The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.
Fiche publication
Date publication
août 2023
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Lelong M, Josien R, Coste-Burel M, Rimbert M, Bressollette-Bodin C, Nancey S, Bouguen G, Allez M, Serrero M, Caillo L, Rouillon C, Blanc P, Laharie D, Olivier R, Peyrin-Biroulet L, Dib N, De Maissin A, Montuclard C, Trang-Poisson C, Vavasseur F, Gallot G, Berthome M, Braudeau C, Chevreuil J, Bourreille A, Le Berre C
Lien Pubmed
Résumé
Patients with inflammatory bowel disease (IBD) may have a modified immune response to SARS-CoV-2. The objectives were to evaluate the prevalence of COVID-19 in patients treated with infliximab or vedolizumab, to analyze the factors associated with the infection, the impact of treatments and trough levels.
Mots clés
Crohn’s disease, SARS-CoV-2, infliximab, trough levels, ulcerative colitis, vedolizumab
Référence
Front Immunol. 2023 08 28;14:1243898